Influence of the duration of type 2 diabetes mellitus on colorectal cancer outcomes.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 08 2023
10 08 2023
Historique:
received:
03
05
2023
accepted:
07
08
2023
medline:
14
8
2023
pubmed:
11
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Type 2 diabetes mellitus (T2DM) is a progressive disease, which affects colorectal cancer (CRC) survival. However, data on the relationship between CRC survival and T2DM duration is scarce and controversial. A retrospective observational study was conducted. Sub-cohorts were created based on the duration of T2DM as follows, ≤ or > 5/10/15/20 years. 204 of the 817 (24.95%) included study participants had T2DM at any point of CRC. 160 of the 204 CRC + T2DM patients had detailed T2DM duration data. At the time of CRC diagnosis, 85, 50, 31, and 11 patients had T2DM for > 5/10/15/20 years, respectively, which increased to 110, 71, 45, and 17 during the course of the study. Despite constant glycated hemoglobin values throughout the study, shorter overall and disease-specific survival times were observed for the > 5/10/15 years cohorts and longitudinal survival modeling techniques confirmed the significant effect of T2DM duration in all cohorts. While in the first 3 years after CRC diagnosis, the best survival was found for the ≤ 5 years cohort, all diabetes cohorts had the same survival thereafter. T2DM duration affected CRC survival significantly, therefore, a closer follow-up of this sub-populations is suggested.
Identifiants
pubmed: 37563292
doi: 10.1038/s41598-023-40216-3
pii: 10.1038/s41598-023-40216-3
pmc: PMC10415401
doi:
Substances chimiques
Glycated Hemoglobin
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12985Informations de copyright
© 2023. Springer Nature Limited.
Références
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249. https://doi.org/10.3322/caac.21660 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
International Diabetes Federation. IDF Diabetes Atlas 10th edn (International Diabetes Federation, 2021).
Shlomai, G., Neel, B., LeRoith, D. & Gallagher, E. J. Type 2 diabetes mellitus and cancer: The role of pharmacotherapy. J. Clin. Oncol. 34, 4261–4269. https://doi.org/10.1200/JCO.2016.67.4044 (2016).
doi: 10.1200/JCO.2016.67.4044
pubmed: 27903154
pmcid: 5455318
DeFronzo, R. A. et al. Type 2 diabetes mellitus. Nat. Rev. Dis. Primers 1, 15019. https://doi.org/10.1038/nrdp.2015.19 (2015).
doi: 10.1038/nrdp.2015.19
pubmed: 27189025
Gonzalez, N. et al. 2017 Update on the relationship between diabetes and colorectal cancer: Epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget 8, 18456–18485. https://doi.org/10.18632/oncotarget.14472 (2017).
doi: 10.18632/oncotarget.14472
pubmed: 28060743
pmcid: 5392343
Petrelli, F. et al. Survival of colorectal cancer patients with diabetes mellitus: A meta-analysis. Can. J. Diabetes 45, 186-197 e182. https://doi.org/10.1016/j.jcjd.2020.06.009 (2021).
doi: 10.1016/j.jcjd.2020.06.009
pubmed: 33039329
Fonseca, V. A. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32(Suppl 2), S151-156. https://doi.org/10.2337/dc09-S301 (2009).
doi: 10.2337/dc09-S301
pubmed: 19875543
pmcid: 2811457
Tao, H. et al. Pre- and post-diagnosis diabetes as a risk factor for all-cause and cancer-specific mortality in breast, prostate, and colorectal cancer survivors: A prospective cohort study. Front. Endocrinol. 11, 60. https://doi.org/10.3389/fendo.2020.00060 (2020).
doi: 10.3389/fendo.2020.00060
Qiang, J. K. et al. Impact of diabetes on colorectal cancer stage and mortality risk: A population-based cohort study. Diabetologia 63, 944–953. https://doi.org/10.1007/s00125-020-05094-8 (2020).
doi: 10.1007/s00125-020-05094-8
pubmed: 31993714
Amshoff, Y. et al. Type 2 diabetes and colorectal cancer survival: The multiethnic cohort. Int. J. Cancer 143, 263–268. https://doi.org/10.1002/ijc.31311 (2018).
doi: 10.1002/ijc.31311
pubmed: 29441528
pmcid: 5980698
Yuan, C. et al. Preexisting type 2 diabetes and survival among patients with colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 30, 757–764. https://doi.org/10.1158/1055-9965.EPI-20-1083 (2021).
doi: 10.1158/1055-9965.EPI-20-1083
pubmed: 33531435
pmcid: 8026573
Gaál, Z. et al. Clinical Practice Guideline—Diagnosis of diabetes, and antihyperglycaemic treatment and care of patients with diabetes in adulthood. Diabetol Hung. 28, 119–204. https://doi.org/10.24121/dh.2020.14 (2020).
doi: 10.24121/dh.2020.14
ElSayed, N. A. et al. 2. Classification and diagnosis of diabetes: Standards of care in diabetes-2023. Diabetes Care 46, S19–S40. https://doi.org/10.2337/dc23-S002 (2023).
doi: 10.2337/dc23-S002
pubmed: 36507649
Li, J., Liu, J., Gao, C., Liu, F. & Zhao, H. Increased mortality for colorectal cancer patients with preexisting diabetes mellitus: An updated meta-analysis. Oncotarget 8, 62478–62488. https://doi.org/10.18632/oncotarget.19923 (2017).
doi: 10.18632/oncotarget.19923
pubmed: 28977962
pmcid: 5617522
Becker, D. J. et al. Diabetes mellitus and colorectal carcinoma outcomes: A meta-analysis. Int. J. Colorectal. Dis. 35, 1989–1999. https://doi.org/10.1007/s00384-020-03666-z (2020).
doi: 10.1007/s00384-020-03666-z
pubmed: 32564124
Le Marchand, L., Wilkens, L. R., Kolonel, L. N., Hankin, J. H. & Lyu, L. C. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res. 57, 4787–4794 (1997).
pubmed: 9354440
Nunez, C., Nair-Shalliker, V., Egger, S., Sitas, F. & Bauman, A. Physical activity, obesity and sedentary behaviour and the risks of colon and rectal cancers in the 45 and up study. BMC Public Health 18, 325. https://doi.org/10.1186/s12889-018-5225-z (2018).
doi: 10.1186/s12889-018-5225-z
pubmed: 29510753
pmcid: 5840833
de Kort, S. et al. Diabetes mellitus, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk. Int. J. Cancer 145, 1774–1781. https://doi.org/10.1002/ijc.32365 (2019).
doi: 10.1002/ijc.32365
pubmed: 31018241
pmcid: 6767781
Giovannucci, E. et al. Diabetes and cancer: A consensus report. Diabetes Care 33, 1674–1685. https://doi.org/10.2337/dc10-0666 (2010).
doi: 10.2337/dc10-0666
pubmed: 20587728
pmcid: 2890380
Lundby, A. et al. Surface-expressed insulin receptors as well as IGF-I receptors both contribute to the mitogenic effects of human insulin and its analogues. J. Appl. Toxicol. 35, 842–850. https://doi.org/10.1002/jat.3082 (2015).
doi: 10.1002/jat.3082
pubmed: 25413577
Overbeek, J. A. et al. Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes. Int. J. Colorectal. Dis. 34, 269–276. https://doi.org/10.1007/s00384-018-3191-7 (2019).
doi: 10.1007/s00384-018-3191-7
pubmed: 30421309
Gross, C. P., McAvay, G. J., Guo, Z. & Tinetti, M. E. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 109, 2410–2419. https://doi.org/10.1002/cncr.22726 (2007).
doi: 10.1002/cncr.22726
pubmed: 17510973
Zanders, M. M. et al. Diminishing differences in treatment between patients with colorectal cancer with and without diabetes: A population-based study. Diabet. Med. 30, 1181–1188. https://doi.org/10.1111/dme.12253 (2013).
doi: 10.1111/dme.12253
pubmed: 23758334
Maas, H. A. A. M. et al. The effects of age and comorbidity on treatment patterns for radiotherapy and survival in patients with mobile rectal cancer: A population-based study. Eur. Geriatr. Med. 2, 273–279. https://doi.org/10.1016/j.eurger.2011.07.007 (2011).
doi: 10.1016/j.eurger.2011.07.007
Lemmens, V. E. et al. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br. J. Surg. 92, 615–623. https://doi.org/10.1002/bjs.4913 (2005).
doi: 10.1002/bjs.4913
pubmed: 15779071
Garcia-Perez, L. E., Alvarez, M., Dilla, T., Gil-Guillen, V. & Orozco-Beltran, D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 4, 175–194. https://doi.org/10.1007/s13300-013-0034-y (2013).
doi: 10.1007/s13300-013-0034-y
pubmed: 23990497
pmcid: 3889324
Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A. & Sakharkar, M. K. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights 11, 95–104. https://doi.org/10.4137/BMI.S38440 (2016).
doi: 10.4137/BMI.S38440
pubmed: 27398023
pmcid: 4933534
ElSayed, N. A. et al. 6. Glycemic targets: Standards of care in diabetes-2023. Diabetes Care 46, S97–S110. https://doi.org/10.2337/dc23-S006 (2023).
doi: 10.2337/dc23-S006
pubmed: 36507646
Desouza, C. V., Bolli, G. B. & Fonseca, V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 33, 1389–1394. https://doi.org/10.2337/dc09-2082 (2010).
doi: 10.2337/dc09-2082
pubmed: 20508232
pmcid: 2875462
Kempler, P. et al. Prevalence and financial burden of type 2 diabetes mellitus in Hungary between 2001–2014—Results of the analysis of the National Health Insurance Fund database. Diab Hung 24, 177–188 (2016).
Sinicrope, F. A. Increasing incidence of early-onset colorectal cancer. N. Engl. J. Med. 386, 1547–1558. https://doi.org/10.1056/NEJMra2200869 (2022).
doi: 10.1056/NEJMra2200869
pubmed: 35443109
Siegel, R. L., Jakubowski, C. D., Fedewa, S. A., Davis, A. & Azad, N. S. Colorectal cancer in the young: Epidemiology, prevention, management. Am. Soc. Clin. Oncol. Educ. Book 40, 1–14. https://doi.org/10.1200/EDBK_279901 (2020).
doi: 10.1200/EDBK_279901
pubmed: 32315236
Xie, J. et al. Global burden of type 2 diabetes in adolescents and young adults, 1990–2019: Systematic analysis of the Global Burden of Disease Study 2019. BMJ 379, e072385. https://doi.org/10.1136/bmj-2022-072385 (2022).
doi: 10.1136/bmj-2022-072385
pubmed: 36740855
pmcid: 9727920
ElSayed, N. A. et al. 10. Cardiovascular disease and risk management: Standards of care in diabetes-2023. Diabet. Care 46, S158–S190. https://doi.org/10.2337/dc23-S010 (2023).
doi: 10.2337/dc23-S010
Farbstein, D. & Levy, A. P. HDL dysfunction in diabetes: Causes and possible treatments. Expert Rev. Cardiovasc. Ther. 10, 353–361. https://doi.org/10.1586/erc.11.182 (2012).
doi: 10.1586/erc.11.182
pubmed: 22390807
pmcid: 3332215
Bramlage, P. et al. Renal function deterioration in adult patients with type-2 diabetes. BMC Nephrol. 21, 312. https://doi.org/10.1186/s12882-020-01952-0 (2020).
doi: 10.1186/s12882-020-01952-0
pubmed: 32727401
pmcid: 7391505
Joshi, R. et al. Prevalence and risk factors of chronic kidney disease among patients with type 2 diabetes mellitus at a tertiary care hospital in Nepal: A cross-sectional study. BMJ Open 13, e067238. https://doi.org/10.1136/bmjopen-2022-067238 (2023).
doi: 10.1136/bmjopen-2022-067238
pubmed: 36854582
pmcid: 9980322
Xie, L. et al. Anemia is a risk factor for rapid eGFR decline in type 2 diabetes. Front. Endocrinol. 14, 1052227. https://doi.org/10.3389/fendo.2023.1052227 (2023).
doi: 10.3389/fendo.2023.1052227
Greten, F. R. & Grivennikov, S. I. Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity 51, 27–41. https://doi.org/10.1016/j.immuni.2019.06.025 (2019).
doi: 10.1016/j.immuni.2019.06.025
pubmed: 31315034
pmcid: 6831096
Herczeg, G. et al. Does diabetes affect paraneoplastic thrombocytosis in colorectal cancer?. Open Med 17, 160–173. https://doi.org/10.1515/med-2021-0407 (2022).
doi: 10.1515/med-2021-0407
Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr. Diabet. Rev. 16, 442–449. https://doi.org/10.2174/1573399815666191024085838 (2020).
doi: 10.2174/1573399815666191024085838
Wozniakova, M., Skarda, J. & Raska, M. The role of tumor microenvironment and immune response in colorectal cancer development and prognosis. Pathol. Oncol. Res. 28, 1610502. https://doi.org/10.3389/pore.2022.1610502 (2022).
doi: 10.3389/pore.2022.1610502
pubmed: 35936516
pmcid: 9350736
Ibrahim, J. G. & Molenberghs, G. Missing data methods in longitudinal studies: A review. Test (Madr) 18, 1–43. https://doi.org/10.1007/s11749-009-0138-x (2009).
doi: 10.1007/s11749-009-0138-x
pubmed: 21218187
Schwandt, A. et al. Comparison of MDRD, CKD-EPI, and Cockcroft–Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes. J. Diabet. Complicat. 31, 1376–1383. https://doi.org/10.1016/j.jdiacomp.2017.06.016 (2017).
doi: 10.1016/j.jdiacomp.2017.06.016
Jessup, J. et al. Colon and rectum. In AJCC Cancer Staging Manual 8th edn (eds Amin, M. et al.) 251–274 (Springer, 2018).
Baran, B. et al. Difference between left-sided and right-sided colorectal cancer: A focused review of literature. Gastroenterol. Res. 11, 264–273. https://doi.org/10.14740/gr1062w (2018).
doi: 10.14740/gr1062w
Argiles, G. et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1291–1305. https://doi.org/10.1016/j.annonc.2020.06.022 (2020).
doi: 10.1016/j.annonc.2020.06.022
pubmed: 32702383
Glynne-Jones, R. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28, iv22–iv40. https://doi.org/10.1093/annonc/mdx224 (2017).
doi: 10.1093/annonc/mdx224
pubmed: 28881920
Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422. https://doi.org/10.1093/annonc/mdw235 (2016).
doi: 10.1093/annonc/mdw235
pubmed: 27380959
Holm, S. A Simple sequentially rejective multiple test procedure. Scand. J. Stat. 6, 65–70 (1979).